H2 Hydrogen Bottle – Family Pack 3+1 Free
In this episode, Prof. Shigeo Ohta and David Maršálek, founder of H2 Global Group, return to the beginning of their “hydrogen” journey. Ohta describes how his academic research gradually led him to the long-term study of molecular hydrogen and why he sees it as a meaningful direction for modern medicine.
Just a few years ago, investments in healthcare and medical innovation were mainly opportunities for large funds, strategic players, and a narrow group of specialized investors. Today, the situation is changing rapidly. Healthcare is becoming one of the world’s main investment themes — not only because of returns, but also because of social necessity: aging populations, high household and public healthcare spending, shortages in care capacity, and the enormous burden placed on families caring for chronically ill relatives.
A Global Problem Without a Simple Solution
Dementia and neurodegenerative diseases are among the greatest challenges of modern medicine today. They affect tens of millions of people worldwide, and their impact is not only medical but also social and economic. The costs of caring for patients with dementia amount to trillions of dollars globally each year and continue to rise as life expectancy increases.
Today in Ostrava, the clinical evaluation of a medical device was officially launched as part of a clinical study aimed at demonstrating the safety of non-invasive molecular hydrogen inhalation in patients with mild cognitive impairment (MCI), a condition that may precede the development of Alzheimer’s dementia.
The study connects a Czech clinical center with a leading Japanese scientific team and represents an important step toward moving molecular hydrogen from the research domain into legitimate, regulated use in healthcare. The project is led by the Czech company H2 Medical Technologies, a member of the H2 Global Group.
PharmDr. Milan Krajíček is a pharmacist and entrepreneur who has spent his entire career combining rigorous expertise, regulatory discipline, and the ability to turn ideas into practice—with a single goal: to ensure that science truly serves people.
When I look back today, I see more than 21 years of my life devoted to a single idea—the belief that even the smallest element in the universe can have a profound significance for humanity.
On Friday, we welcomed Professor Shigeo Ohta in the Czech Republic, a globally respected authority in the field of molecular hydrogen and Co-Founder of H2 Global Group.
Prague, December 19, 2025 (PROTEXT) – Dementia and Alzheimer’s disease are rapidly becoming one of the most significant health, social, and economic challenges of our time—and even more so of the decades ahead. Alzheimer’s dementia is often referred to as the “cancer of the mind.” In its early stages, it does not progress dramatically from one day to the next, but rather slowly and insidiously takes away a person’s memory, identity, and independence. The impact does not fall solely on patients themselves, but also on their families, healthcare systems, and public budgets.
A unique experiment is being prepared in Ostrava. For the first time in the Czech Republic, physicians will examine the effect of hydrogen on the risk and early symptoms of Alzheimer’s dementia. Inhaling molecular hydrogen could help delay memory problems and improve quality of life. The clinical study has already received all the necessary approvals and is now seeking volunteers to take part.
Prague, December 3, 2025 (PROTEXT) – The longevity market is experiencing a global boom. An increasing number of people are becoming aware of the vast possibilities offered by today’s modern world, and the desire to live to an advanced age in good physical and mental condition, without serious health problems, is steadily growing. What was until recently a niche domain associated mainly with biohackers and enthusiasts is now becoming a serious, multi-disciplinary industry, attracting investors, healthcare and pharmaceutical groups, as well as luxury wellness brands.
According to expert estimates, the global longevity market could reach a value of approximately USD 1.87 trillion by 2034. Success in this rapidly expanding sector will belong to projects capable of combining clinical credibility, measurable results, and premium services.
For several years now, the technological standard in this field has been set by the Czech group H2 Global Group, which specializes in the use of molecular hydrogen in medicine, longevity, beauty, and sports, supported by its subsidiaries H2 Medical Technologies, H2 Pharm, and H2 Longevity Lifestyle.
Alzheimer’s dementia is one of the greatest challenges facing not only an aging society. It can affect any of us at any time—directly, within our families, or among those close to us—and at a certain stage, patients may no longer even be aware of the disease themselves. It places an enormous burden on families, healthcare systems, and the economy, while also raising a fundamental question: will we remain passive observers, or will we actively engage in the search for new, gentler solutions?
Ostrava, November 24, 2025 (PROTEXT) – According to the World Health Organization (WHO), depression, anxiety, and other mental health conditions cost the global economy approximately 12 billion working days each year, representing a loss of around one trillion US dollars. As a result, companies and HR professionals are increasingly seeking new ways to reduce employee stress, improve recovery, and lower absenteeism. One of the tools that, alongside traditional programs, is now beginning to appear in the corporate environment is molecular hydrogen.
It has been almost 14 years since David Maršálek happened to meet Professor Dušan Miljkovič in the United States—the man who was the first in the world to introduce a hydrogen-based dietary supplement. This moment marked the beginning of a journey that has led to a project with global ambitions today.
On 12 November 2025, a press conference of H2 Medical Technologies, part of H2 Global Group, was held at the ČTK PressCentre. At this event, we announced a major milestone – the approval of the first clinical study by the State Institute for Drug Control (SÚKL) in the Czech Republic, focused on inhalation of molecular hydrogen in patients with mild cognitive impairment (MCI).
Ostrava, October 21, 2025 – The Czech group H₂ Global Group has announced a historic milestone. The State Institute for Drug Control (SÚKL) has officially approved a clinical trial conducted by H₂ Medical Technologies, a subsidiary of H2 Global Group, focused on the inhalation of molecular hydrogen in patients with mild cognitive impairment (MCI)—a condition that often precedes the development of Alzheimer’s dementia.
The Czech company H2 Global Group, a global leader in HealthTech and MedTech with more than 13 years of research and development in the field of Molecular Hydrogen®, is introducing its next exclusive project – the H2 Longevity® Center for Healthy Longevity.
The Czech group H2 Global Group, together with its subsidiary H2 Medical Technologies, achieved a significant success at the international LSI Europe 2025 conference. As the sole representative of the Czech MedTech and HealthTech sector, it presented its unique approach to the prevention and treatment of neurodegenerative diseases, including Alzheimer’s dementia, to global investors, thereby confirming its status as a global leader in the field.